Product Information
HYDROXYCHLOROQUINE 300 MG TAB is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $0.5302 per EA under NDC 43598013201. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on May 1, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the HYDROXYCHLOROQUINE SULFATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
Dr. Reddy's Laboratories Inc.NDC
43598013201
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROXYCHLOROQUINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA210441FDA Approved
5/1/2018
TE Code
AB
On Market Since
10/24/2022
Pharmacological Classes
Price Statistics
The NADAC for HYDROXYCHLOROQUINE 300 MG TAB has been published 129 times since Apr 17, 2024, and over the history we have for it it has risen 18.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5302 per EA |
|---|---|
| All-time high | $0.5466 (Mar 11, 2026) |
| All-time low | $0.3442 (Feb 19, 2025) |
| 52-week high | $0.5466 |
| 52-week low | $0.5259 |
| Median price | $0.4942 |
| Average price | $0.4787 |
| Largest weekly change | +15.2% (Jun 18, 2025) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the HYDROXYCHLOROQUINE SULFATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Dr. Reddy's Laboratories Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
HYDROXYCHLOROQUINE SULFATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimalarial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HYDROXYCHLOROQUINE 300 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for HYDROXYCHLOROQUINE 300 MG TAB, manufactured by Dr. Reddy's Laboratories Inc., is $0.5302 per EA (NDC 43598013201), effective Sep 30, 2026.
How has the price of HYDROXYCHLOROQUINE 300 MG TAB changed over time?
Over the history we have for it, the NADAC for HYDROXYCHLOROQUINE 300 MG TAB has risen 18.5%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for HYDROXYCHLOROQUINE 300 MG TAB?
Since Apr 17, 2024, the NADAC for HYDROXYCHLOROQUINE 300 MG TAB has ranged from a low of $0.3442 (Feb 19, 2025) to a high of $0.5466 (Mar 11, 2026), with a median of $0.4942 per EA.
Are there cheaper alternatives to HYDROXYCHLOROQUINE 300 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of HYDROXYCHLOROQUINE 300 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures HYDROXYCHLOROQUINE 300 MG TAB?
HYDROXYCHLOROQUINE 300 MG TAB (NDC 43598013201) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.